Pathogenetic processes

Pathogenetic processes (PPs) — are major molecular and phenotypic characteristics that determinate cancer as complex evolutionary disease process.


Name ( total associations | neutral | plus | minus )


adhesion ( 53 / 29 /
8
/
16
)
Angiogenesis ( 296 / 153 /
50
/
93
)
Anoikis ( 28 / 15 /
5
/
8
)
Antiapoptosis ( 37 / 20 /
12
/
5
)
Apoptosis ( 1942 / 985 /
612
/
345
)
Autophagy ( 464 / 233 /
105
/
126
)
beta-catenin signaling ( 73 / 37 /
14
/
22
)
cell cycle ( 260 / 136 /
45
/
79
)
cell cycle arrest ( 515 / 261 /
226
/
28
)
Cell growth ( 814 / 411 /
123
/
280
)
Chemoresistance ( 294 / 148 /
57
/
89
)
colony formation ( 531 / 271 /
71
/
189
)
differentiation ( 95 / 48 /
31
/
16
)
DNA repair ( 61 / 31 /
21
/
9
)
EMT ( 945 / 479 /
193
/
273
)
growth ( 222 / 131 /
26
/
65
)
inflammation ( 107 / 54 /
22
/
31
)
Invasion ( 3869 / 1960 /
629
/
1280
)
MET ( 18 / 10 /
8
/
)
Metastasis ( 1191 / 604 /
242
/
345
)
migration ( 3079 / 1555 /
491
/
1033
)
motility ( 213 / 109 /
33
/
71
)
NF-kB signaling ( 225 / 114 /
59
/
52
)
Oxaliplatin ( 2 / 1 /
1
/
)
Oxaliplatin resistance ( 31 / 16 /
7
/
8
)
Paclitaxel resistance ( 67 / 34 /
13
/
20
)
Proliferation ( 4396 / 2218 /
715
/
1463
)
Radioresistance ( 145 / 74 /
27
/
44
)
Senescence ( 75 / 41 /
26
/
8
)
stemness ( 245 / 123 /
55
/
67
)
survival ( 134 / 69 /
23
/
42
)
Tamoxifen resistance ( 23 / 12 /
8
/
3
)
5fluorouracil resistance ( 126 / 72 /
23
/
31
)
AKT signaling ( 313 / 158 /
55
/
100
)
cell viability ( 320 / 164 /
40
/
116
)
cisplatin resistance ( 356 / 179 /
61
/
116
)
doxorubicin resistance ( 85 / 43 /
13
/
29
)
ERK pathway (MAPK pathway) ( 191 / 96 /
31
/
64
)
etoposide ( 7 / 4 /
2
/
1
)
Liver metastasis ( 28 / 16 /
4
/
8
)
G1-S checkpoint ( 7 / 4 /
2
/
1
)
multidrug resistance ( 22 / 12 /
5
/
5
)
RAS signaling pathway ( 10 / 6 /
2
/
2
)
tumor growth ( 880 / 443 /
151
/
286
)
cancer progression ( 16 / 9 /
5
/
2
)
cell cycle progression ( 189 / 96 /
46
/
47
)
Lung metastasis ( 65 / 34 /
14
/
17
)
PI3K signaling ( 103 / 52 /
19
/
32
)
WNT signaling ( 390 / 196 /
88
/
106
)
anchorage-independent growth ( 37 / 19 /
10
/
8
)
Bone metastasis ( 26 / 15 /
3
/
8
)
Castrate Resistance ( 27 / 16 /
9
/
2
)
Hedgehog (Hh) signaling ( 32 / 17 /
5
/
10
)
myeloid differentiation ( 27 / 14 /
7
/
6
)
tumor-stroma interactions ( 3 / 2 /
1
/
)
Adriamycin (Adr) resistance ( 30 / 16 /
4
/
10
)
aerobic glycolysis ( 79 / 40 /
12
/
27
)
docetaxel resistance ( 43 / 23 /
15
/
5
)
epirubicin resistance ( 5 / 3 /
2
/
)
gefitinib resistance ( 34 / 18 /
4
/
12
)
JAK/STAT signaling ( 114 / 58 /
30
/
26
)
mTOR signaling ( 92 / 46 /
12
/
34
)
Necrosis ( 6 / 3 /
2
/
1
)
NOTCH signaling ( 91 / 46 /
23
/
22
)
P38 signaling ( 33 / 17 /
10
/
6
)
poor prognosis ( 46 / 26 /
17
/
3
)
Transformation ( 15 / 12 /
2
/
1
)
tumor progression ( 82 / 42 /
24
/
16
)
Tumorigenesis ( 43 / 22 /
7
/
14
)
unfolded protein response ( 7 / 5 /
1
/
1
)
Vorinostat Resistance ( 6 / 4 /
2
/
)
cytotoxicity ( 2 / 1 /
1
/
)
TGF-beta signaling ( 452 / 251 /
103
/
98
)
Temozolomide (TMZ) resistance ( 38 / 19 /
6
/
13
)
BMP signaling ( 233 / 126 /
72
/
35
)
Lapatinib resistance ( 6 / 3 /
1
/
2
)
daunorubicin (DNR) Resistance ( 4 / 2 /
2
/
)
T cell activation ( 3 / 2 /
1
/
)
gemcitabine resistance ( 58 / 29 /
9
/
20
)
genomic instability ( 4 / 2 /
1
/
1
)
Sorafenib resistance ( 36 / 18 /
6
/
12
)
glucose metabolism ( 18 / 9 /
3
/
6
)
BRCAness ( 2 / 1 /
1
/
)
BRAFi resistance ( 4 / 2 /
1
/
1
)
MEKi resistance ( 4 / 2 /
1
/
1
)
immunoevasion ( 26 / 13 /
7
/
6
)
Hippo signaling pathway ( 176 / 88 /
66
/
22
)
fibrosis ( 38 / 19 /
7
/
12
)
MAPK/JNK Signaling Pathway ( 20 / 10 /
5
/
5
)
carboplatin resistance ( 4 / 2 /
1
/
1
)
Hypoxic response ( 10 / 6 /
4
/
)
Taxanes (paclitaxel and docetaxel) resistance ( 16 / 11 /
3
/
2
)
Trastuzumab resistance ( 16 / 8 /
5
/
3
)
TRAIL resistance ( 16 / 8 /
5
/
3
)
Cetuximab resistance ( 20 / 10 /
7
/
3
)
pyroptosis ( 16 / 8 /
7
/
1
)
Sunitinib resistance ( 8 / 4 /
4
/
)
tumor-initiating properties ( 9 / 6 /
/
3
)
ER stress ( 28 / 15 /
/
13
)
cell spreading ( 8 / 6 /
/
2
)
inflammatory monocyte recruitment ( 4 / 3 /
/
1
)
Imatinib resistance ( 18 / 11 /
/
7
)
NK cell cytotoxicity ( 6 / 4 /
/
2
)
Camptothecin resistance ( 3 / 2 /
/
1
)
disease-free survival ( 3 / 2 /
/
1
)
EGFR-TKI resistance ( 4 / 3 /
/
1
)
MTX resistance ( 3 / 2 /
/
1
)
Osteolysis ( 5 / 3 /
/
2
)
gluconeogenesis ( 4 / 2 /
/
2
)
lipogenesis ( 23 / 12 /
/
11
)
Afatinib resistance ( 2 / 1 /
/
1
)
Neratinib resistance ( 2 / 1 /
/
1
)
Brain metastasis ( 2 / 1 /
/
1
)
Rapamycin resistance ( 2 / 1 /
/
1
)
BCL2 inhibitors resistance ( 2 / 1 /
/
1
)
Antiviral response ( 3 / 2 /
/
1
)
branching-morphogenesis ( 1 / 1 /
0
/
0
)
cell polarity ( 1 / 1 /
0
/
0
)
cellular repair of DNA double-strand breaks ( 1 / 1 /
0
/
0
)
chondrogenesis ( 1 / 1 /
0
/
0
)
cyclophosphamide sensitivity ( 1 / 1 /
0
/
0
)
endothelial-mesenchymal transition ( 1 / 1 /
0
/
0
)
erythropoiesis ( 3 / 3 /
0
/
0
)
glycolysis ( 13 / 13 /
0
/
0
)
HCPT (Hydroxycamptothecin) resistantance ( 1 / 1 /
0
/
0
)
Hepatocyte differentation ( 2 / 2 /
0
/
0
)
insulin signaling ( 1 / 1 /
0
/
0
)
macrophage attraction ( 1 / 1 /
0
/
0
)
microtubule-targeting drugs ( 4 / 4 /
0
/
0
)
mitoxantrone (MX) Resistance ( 1 / 1 /
0
/
0
)
neutrophil chemotaxis ( 2 / 2 /
0
/
0
)
recurrence ( 2 / 2 /
0
/
0
)
redox homeostasis ( 3 / 3 /
0
/
0
)
Response to oxidative stress ( 12 / 12 /
0
/
0
)
Response to genotoxic stress ( 2 / 2 /
0
/
0
)
scattering ( 1 / 1 /
0
/
0
)
Tomudex (TDX) resistance ( 1 / 1 /
0
/
0
)
Tyrosine kinase inhibitors (TKIs) resistance ( 1 / 1 /
0
/
0
)
Vinblastine (Velban) resistance ( 1 / 1 /
0
/
0
)